Anti f4 80 clone c1 a3 1

Manufactured by Abcam

Sourced in United Kingdom

Anti-F4/80 (clone C1:A3–1) is a lab equipment product that can be used to detect the F4/80 antigen. F4/80 is a glycoprotein expressed on the surface of mouse macrophages. This antibody can be used in various applications such as flow cytometry and immunohistochemistry to identify and study macrophages.

Automatically generated - may contain errors

Lab products found in correlation

Antibody diluent, by Zytomed Systems (1 mentions) Axioskop 2 mot plus fluorescence microscope, by Zeiss (1 mentions) Axiocam mrc camera, by Zeiss (1 mentions) Plan apochromat, by Zeiss (1 mentions) Alexa fluor 488 and 594 conjugated secondary antibody, by Thermo Fisher Scientific (1 mentions) Anti cd68 clone pg mi, by Agilent Technologies (1 mentions) Axiovision software 4, by Zeiss (1 mentions) Anti cd31, by Agilent Technologies (1 mentions) Anti ki67, by Agilent Technologies (1 mentions) Anti ki67, by Abcam (1 mentions) Vectastain abc kit, by Vector Laboratories (1 mentions) Anti cd31, by Dianova (1 mentions)

2 protocols using anti f4 80 clone c1 a3 1

Quantification of Macrophage Subsets in Tumors

Check if the same lab product or an alternative is used in the 5 most similar protocols

Human monocytes/macrophages were fixed with methanol and stained with anti-CD68 (clone PG-MI, Cat: M 0876; Dako; 1:100) and anti-CD206 (MR) (clone 309210, Cat: MAB2534; R&D Systems; 1:100) antibodies diluted in Antibody Diluent (Zytomed Systems). The signal was detected using Alexa Fluor 488 and 594 conjugated secondary antibodies (Molecular Probes) and the samples were imaged with an Axioskop 2 mot plus fluorescence microscope equipped with Plan-APOCHROMAT 20×/0.8 NA and 40×/0.95 NA objectives and an AxioCam MRc camera with AxioVision software 4.7.1 (Carl Zeiss AG). The staining intensity was quantified using ImageJ software and the percentage of CD68⁺ cells that were also MR-positive was determined.
Frozen tumors sections (7 μm) were stained with anti-F4/80 (clone C1:A3–1, Cat: ab6640; Abcam; 1:100) and anti-MR (Cat: AF535; R&D Systems; 1:250) antibodies, and tumor-draining LNs with anti-CD169 antibody (clone 3D6.112, Cat: MCA884F; Serotec; 1:100) as described above.

Hollmén M., Karaman S., Schwager S., Lisibach A., Christiansen A.J., Maksimow M., Varga Z., Jalkanen S, & Detmar M. (2015). G-CSF regulates macrophage phenotype and associates with poor overall survival in human triple-negative breast cancer. Oncoimmunology, 5(3), e1115177.

+ Open protocol

+ Expand

Immunohistochemistry protocol for tissue analysis

Check if the same lab product or an alternative is used in the 5 most similar protocols

The entire mammary fat pad and a sample of liver was excised from all animals at the end of the treatment period. Tissue was fixed in 10% formalin and paraffin embedded. 5 μm sections from each formalin-fixed paraffin-embedded tissue were stained with haematoxylin and eosin (H&E). Antigen retrieval specific to each antibody was performed as follows: by incubation with trypsin (anti-F4/80); by heating in 0.05% tween in Tris-EDTA buffer (anti-Ki67) or by incubation in antigen retrieval buffer (Dako, anti-CD31) [18 (link)]. Blocking was performed with rabbit or goat serum and slides were incubated with the primary antibody for one hour at room temperature [anti-F4/80 Clone C1:A3-1 (abcam, Cambridge, UK) 1:50 dilution, anti-Ki67 (abcam) 1:1000 dilution] or overnight at 4°C [anti-CD31 (Dianova GmbH, Hamburg, Germany) 1:200 dilution] [18 (link)]. Sections were incubated with secondary antibodies raised to the appropriate species using the Vectastain ABC kit (Vector Laboratories Ltd, Peterborough, UK) followed by DAB chromogenic detection.

Rumney R.M., Coffelt S.B., Neale T.A., Dhayade S., Tozer G.M, & Miller G. (2017). PyMT-Maclow: A novel, inducible, murine model for determining the role of CD68 positive cells in breast tumor development. PLoS ONE, 12(12), e0188591.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!